62 Result(s)
within
English
Medicine & Public Health
Metabolic Diseases
Pharmacology/Toxicology
Yi** **
Conference Paper
-
Chapter and Conference Paper
Clinical Trial to Investigate the Efficacy and Tolerability of Acarbose in Type II Diabetic Patients Treated with Diet Alone
In a biometrically planned observational trial the α-glucosidase inhibitor acarbose (BAY g 5421) has been studied in five type II diabetics who were poorly controlled with diet alone (dietary failure; age, 70 ...
-
Chapter and Conference Paper
Acarbose Does Not Affect Glibenclamide Pharmacokinetics in Type II Diabetic Patients
The α-glucosidase inhibitor acarbose (BAY-g-5421) has been proposed as a useful additional means for improving metabolic control of sulfonylurea-treated type II diabetic patients. Since it results in carbohydr...
-
Chapter and Conference Paper
Efficacy of the Glucosidase Inhibitor Acarbose Compared to the Sulfonylurea Glisoxepide on Metabolic Control in Diet-Treated Type II Diabetics
α-Glucosidase inhibition is a new principle in the treatment of diabetes mellitus. To compare this new principle with the well-established sulfonylurea therapy of type II diabetes, we treated 20 type II diabet...
-
Chapter and Conference Paper
The Long-Term Effects of Acarbose on Type II Diabetics on Diet or Oral Agents
In previous studies [1, 2] we have shown that acarbose, an α-glucosidase inhibitor which slows carbohydrate absorption, can decrease insulin requirements of diabetics, as assessed in acute experiments with the...
-
Chapter and Conference Paper
Acarbose in the Treatment of NIDDM Patients with Hyperlipidemia
Acarbose is a glucosidase inhibitor which is currently being tested in clinical trials for the treatment of diabetes mellitus and hyperlipidemia. We report here preliminary observations obtained in six patient...
-
Chapter and Conference Paper
Introduction
Welcome to the second international symposium on acarbose.
-
Chapter and Conference Paper
Effects of Low-Dose Acarbose on Glycemia, Adiposity, and Cholesterolemia in Obese and Obese Non-Insulin-Dependent Diabetic Corpulent Rats
To determine the effects of low-dose acarbose (ACB; BAY g 5421; 100 mg/kg diet) on modulation of adiposity, carbohydrate, and lipid metabolism, groups of congenic, pathogen-free male lean and obese LA/N-cp and...
-
Chapter and Conference Paper
Effect of Acarbose on Blood Glucose and Insulin Response to a Sucrose Load in Subjects with Reactive Hypoglycemia
The aim of the present study was to evaluate the acute effect of acarbose on glycemic and insulin response to an oral sucrose load in patients with reactive hypoglycemia. Sixteen patients (13 women, 3 men; age...
-
Chapter and Conference Paper
Acarbose Treatment and Sulfonylurea Secondary Failure
Acarbose has now been investigated in a great number of diabetic patients (Hillebrand 1987). The main indication for this drug is treatment of hyperglycemia in type II diabetic patients. The efficiency of acar...
-
Chapter and Conference Paper
Discussion
-
Chapter and Conference Paper
Enhancement of Insulin Binding and Glucose Transport by Acarbose in Adipocytes of Zucker Rats
Acarbose (BAY g 5421) is an intestinal α-glucosidase inhibitor which slows carbohydrate digestion and the rate of glucose absorption from the gut. To test whether longterm administration of acarbose alters adi...
-
Chapter and Conference Paper
Acarbose Treatment in Insulin-Dependent (Type I) Diabetes Mellitus
We all know well that during the last 30 years not a single new medication has been discovered which would present a mode of action different from that the established medications for the therapy of diabetes m...
-
Chapter and Conference Paper
Clinical Studies with Acarbose for the Control of Hyperglycemia which is the Major Pathogenetic Factor of the Complications of Diabetes Mellitus
The pathogenesis of the long-term complications of diabetes mellitus is still not resolved. It is still not unanimously accepted that hyperglycemia is the underlying cause of the complications of diabetes mell...
-
Chapter and Conference Paper
Discussion
-
Chapter and Conference Paper
Effects of Acarbose on Cardiac and Hepatic Metabolism in Diabetic Rats
We have studied the effects of the inclusion of acarbose in a high carbohydrate diet fed to rats with type I diabetes (streptozotocin-treated) and to rats with genetically induced type II diabetes (SHR/N-cp ra...
-
Chapter and Conference Paper
Inhibition of α-Glucosidase by Acarbose as an Additional Tool for Glycemia Control in Insulin-Dependent Diabetics on Conventional Insulin Therapy
In spite of its intensification, conventional insulin therapy is often not effective in limiting the postprandial glycemia excursions to planned areas. The practical problem entailed by this served as the moti...
-
Chapter and Conference Paper
Discussion
-
Chapter and Conference Paper
The Effectiveness of Acarbose in the Reduction of Diabetic Symptoms and Neuropathic Complications in a NIDDM Animal Model
Acarbose was administered to Wistar fatty diabetic rats to reduce the symptoms of diabetes and thus the neuropathic complications of the hyperglycemic state. All diets were composed of Purina 5008 chow, contai...
-
Chapter and Conference Paper
Long-Term Metabolic Effects of Acarbose in Healthy Young Men
To explore the long-term metabolic effects of acarbose in man, six healthy men (25 ± 2 years of age; BMI, 21.6 ± 2.7, mean ± SD) were fed a controlled diet in a metabolic ward for 7 consecutive weeks. After an...
-
Chapter and Conference Paper
Nonrandomized Follow-up Study with Acarbose Treatment and Pre- and Post-treatment with Placebo in Type I Diabetic Children
In a nonrandomized follow-up study 12 patients with insulin-dependent diabetes mellitus (IDDM) were treated under hospital conditions (after a 7-day preliminary period) with placebo for 10 days, then acarbose ...
